TY  - JOUR
AU  - Becarević, Mirjana
AU  - Sarić, Marija
AU  - Stojanović, Ljudmila
AU  - Mirković, Duško
AU  - Dopsaj, Violeta
AU  - Ignjatović, Svetlana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3063
AB  - Vascular antiphospholipid syndrome (VAPS) and obstetric (OAPS) are different entities because some patients only develop thrombosis (without recurrent pregnancy losses) and vice versa. Only two articles have reported that low 25-hydroxy-cholecalciferol (vitamin D3, VD3) levels were not correlated with the presence of conventional antiphospholipid antibodies (aPL Abs: anticardiolipin (aCL), anti-beta2glycoprotein I (a2gpI), and lupus anticoagulant (LA)), but no article analyzed the association of VD3 and anti-annexin A5 (aanxA5) Abs. The aim of our study was to investigate the association between VD3, multiple positivity of conventional aPL and aanxA5 Abs levels only in female OAPS vs. VAPS. Our study included 62 consecutive female PAPS patients. Concentrations of Abs were measured by ELISA, while VD3 levels were determined by immunochemiluminescence. Only 10/62 (16.13%) had sufficient (30ng/ml) VD3 levels, while 48/62 (77.42%) and 4/62 (6.45%) had insufficiency and VD3 deficiency, respectively. Statistically significant VD3 deficiency was noticed in VAPS (vs. OAPS, P=0.013). A negative correlation between VD3 levels and the age of patients was noticed (r=-0.493, P=0.032) only in VAPS subgroup. Multiple positivity of aPL and aanxA5 Abs was not associated with VD3 deficiency. Newly emerging aPL Abs, such as aanxA5 Abs, or their combinations with classical aPL Abs are not associated with VD3 deficiency in neither OAPS nor VAPS patients. Due to its immunomodulatory roles in B-Ly homeostasis, supplementation with VD3 should be considered in APS, at least in subgroup with severe form of the disease, i.e., VAPS.
PB  - Springer London Ltd, London
T2  - Clinical Rheumatology
T1  - Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome
VL  - 37
IS  - 12
SP  - 3359
EP  - 3364
DO  - 10.1007/s10067-018-4170-7
ER  - 

@article{
author = "Becarević, Mirjana and Sarić, Marija and Stojanović, Ljudmila and Mirković, Duško and Dopsaj, Violeta and Ignjatović, Svetlana",
year = "2018",
abstract = "Vascular antiphospholipid syndrome (VAPS) and obstetric (OAPS) are different entities because some patients only develop thrombosis (without recurrent pregnancy losses) and vice versa. Only two articles have reported that low 25-hydroxy-cholecalciferol (vitamin D3, VD3) levels were not correlated with the presence of conventional antiphospholipid antibodies (aPL Abs: anticardiolipin (aCL), anti-beta2glycoprotein I (a2gpI), and lupus anticoagulant (LA)), but no article analyzed the association of VD3 and anti-annexin A5 (aanxA5) Abs. The aim of our study was to investigate the association between VD3, multiple positivity of conventional aPL and aanxA5 Abs levels only in female OAPS vs. VAPS. Our study included 62 consecutive female PAPS patients. Concentrations of Abs were measured by ELISA, while VD3 levels were determined by immunochemiluminescence. Only 10/62 (16.13%) had sufficient (30ng/ml) VD3 levels, while 48/62 (77.42%) and 4/62 (6.45%) had insufficiency and VD3 deficiency, respectively. Statistically significant VD3 deficiency was noticed in VAPS (vs. OAPS, P=0.013). A negative correlation between VD3 levels and the age of patients was noticed (r=-0.493, P=0.032) only in VAPS subgroup. Multiple positivity of aPL and aanxA5 Abs was not associated with VD3 deficiency. Newly emerging aPL Abs, such as aanxA5 Abs, or their combinations with classical aPL Abs are not associated with VD3 deficiency in neither OAPS nor VAPS patients. Due to its immunomodulatory roles in B-Ly homeostasis, supplementation with VD3 should be considered in APS, at least in subgroup with severe form of the disease, i.e., VAPS.",
publisher = "Springer London Ltd, London",
journal = "Clinical Rheumatology",
title = "Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome",
volume = "37",
number = "12",
pages = "3359-3364",
doi = "10.1007/s10067-018-4170-7"
}

Becarević, M., Sarić, M., Stojanović, L., Mirković, D., Dopsaj, V.,& Ignjatović, S.. (2018). Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome. in Clinical Rheumatology
Springer London Ltd, London., 37(12), 3359-3364.
https://doi.org/10.1007/s10067-018-4170-7

Becarević M, Sarić M, Stojanović L, Mirković D, Dopsaj V, Ignjatović S. Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome. in Clinical Rheumatology. 2018;37(12):3359-3364.
doi:10.1007/s10067-018-4170-7 .

Becarević, Mirjana, Sarić, Marija, Stojanović, Ljudmila, Mirković, Duško, Dopsaj, Violeta, Ignjatović, Svetlana, "Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome" in Clinical Rheumatology, 37, no. 12 (2018):3359-3364,
https://doi.org/10.1007/s10067-018-4170-7 . .

TY  - CONF
AU  - Stojanović, Ljudmila
AU  - Stanisavljević, Nataša
AU  - Marisavljević, D.
AU  - Dopsaj, Violeta
AU  - Todić, B.
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2648
PB  - BMJ PUBLISHING GROUP, LONDON
C3  - Annals of the Rheumatic Diseases
T1  - The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome
VL  - 75
IS  - Supplement 2
SP  - 284
EP  - 284
DO  - 10.1136/annrheumdis-2016-eular.1782
ER  - 

@conference{
author = "Stojanović, Ljudmila and Stanisavljević, Nataša and Marisavljević, D. and Dopsaj, Violeta and Todić, B.",
year = "2016",
publisher = "BMJ PUBLISHING GROUP, LONDON",
journal = "Annals of the Rheumatic Diseases",
title = "The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome",
volume = "75",
number = "Supplement 2",
pages = "284-284",
doi = "10.1136/annrheumdis-2016-eular.1782"
}

Stojanović, L., Stanisavljević, N., Marisavljević, D., Dopsaj, V.,& Todić, B.. (2016). The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome. in Annals of the Rheumatic Diseases
BMJ PUBLISHING GROUP, LONDON., 75(Supplement 2), 284-284.
https://doi.org/10.1136/annrheumdis-2016-eular.1782

Stojanović L, Stanisavljević N, Marisavljević D, Dopsaj V, Todić B. The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome. in Annals of the Rheumatic Diseases. 2016;75(Supplement 2):284-284.
doi:10.1136/annrheumdis-2016-eular.1782 .

Stojanović, Ljudmila, Stanisavljević, Nataša, Marisavljević, D., Dopsaj, Violeta, Todić, B., "The oxidative stress markers as risk factor for endothelial dysfunction in primary and secondary antiphospholipid syndrome" in Annals of the Rheumatic Diseases, 75, no. Supplement 2 (2016):284-284,
https://doi.org/10.1136/annrheumdis-2016-eular.1782 . .

TY  - JOUR
AU  - Stanisavljević, Nataša
AU  - Stojanović, Ljudmila
AU  - Marisavljević, D.
AU  - Đoković, A.
AU  - Dopsaj, Violeta
AU  - Kotur-Stevuljević, Jelena
AU  - Martinović, Jelena
AU  - Memon, Lidija
AU  - Radovanović, Slavica
AU  - Todić, B.
AU  - Lisulov, D.
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2710
AB  - The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Oxidative stress dominates in APS patients. LOOH and AOPP correlate to lipid fractions (p  lt  0.05), unlike PON1, tSHG that correlated to antiphospholipid antibody positivity (p  lt  0.05). FMD was lower in APS patients comparing to controls (p  lt  0.001). Cholesterol is independent variable for FMD impairment in control group (p = 0.011); LOOH in PAPS (p = 0.004); LOOH, aCL, and triglycerides in SAPS patients (p = 0.009, p = 0.049, and p = 0.012, respectively). Combined predictive of aCL and LOOH is better for FMD impairment than LOOH alone in both PAPS and SAPS patients (AUC 0.727, p = 0.001, 95 % CI 0.616-0.837 and AUC 0.824, pE,0.001, 95 % CI 0.690-0.957, respectively). Lipid peroxidation is independent predictor for endothelial dysfunction in APS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients.
PB  - Springer London Ltd, London
T2  - Clinical Rheumatology
T1  - Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients
VL  - 35
IS  - 10
SP  - 2485
EP  - 2493
DO  - 10.1007/s10067-016-3369-8
ER  - 

@article{
author = "Stanisavljević, Nataša and Stojanović, Ljudmila and Marisavljević, D. and Đoković, A. and Dopsaj, Violeta and Kotur-Stevuljević, Jelena and Martinović, Jelena and Memon, Lidija and Radovanović, Slavica and Todić, B. and Lisulov, D.",
year = "2016",
abstract = "The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Oxidative stress dominates in APS patients. LOOH and AOPP correlate to lipid fractions (p  lt  0.05), unlike PON1, tSHG that correlated to antiphospholipid antibody positivity (p  lt  0.05). FMD was lower in APS patients comparing to controls (p  lt  0.001). Cholesterol is independent variable for FMD impairment in control group (p = 0.011); LOOH in PAPS (p = 0.004); LOOH, aCL, and triglycerides in SAPS patients (p = 0.009, p = 0.049, and p = 0.012, respectively). Combined predictive of aCL and LOOH is better for FMD impairment than LOOH alone in both PAPS and SAPS patients (AUC 0.727, p = 0.001, 95 % CI 0.616-0.837 and AUC 0.824, pE,0.001, 95 % CI 0.690-0.957, respectively). Lipid peroxidation is independent predictor for endothelial dysfunction in APS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients.",
publisher = "Springer London Ltd, London",
journal = "Clinical Rheumatology",
title = "Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients",
volume = "35",
number = "10",
pages = "2485-2493",
doi = "10.1007/s10067-016-3369-8"
}

Stanisavljević, N., Stojanović, L., Marisavljević, D., Đoković, A., Dopsaj, V., Kotur-Stevuljević, J., Martinović, J., Memon, L., Radovanović, S., Todić, B.,& Lisulov, D.. (2016). Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. in Clinical Rheumatology
Springer London Ltd, London., 35(10), 2485-2493.
https://doi.org/10.1007/s10067-016-3369-8

Stanisavljević N, Stojanović L, Marisavljević D, Đoković A, Dopsaj V, Kotur-Stevuljević J, Martinović J, Memon L, Radovanović S, Todić B, Lisulov D. Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. in Clinical Rheumatology. 2016;35(10):2485-2493.
doi:10.1007/s10067-016-3369-8 .

Stanisavljević, Nataša, Stojanović, Ljudmila, Marisavljević, D., Đoković, A., Dopsaj, Violeta, Kotur-Stevuljević, Jelena, Martinović, Jelena, Memon, Lidija, Radovanović, Slavica, Todić, B., Lisulov, D., "Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients" in Clinical Rheumatology, 35, no. 10 (2016):2485-2493,
https://doi.org/10.1007/s10067-016-3369-8 . .

TY  - JOUR
AU  - Becarević, Mirjana
AU  - Stojanović, Ljudmila
AU  - Ignjatović, Svetlana
AU  - Dopsaj, Violeta
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2590
AB  - We evaluated the importance of anti-annexin A5 antibodies (aanxA5 Abs) for clinical (thrombosis and/or recurrent pregnancy loss) and serologic (presence of antiphospholipid antibodies: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta 2 glycoprotein I (a beta 2GPI) antibodies) features of patients with primary antiphospholipid syndrome (PAPS). Our study included 70 patients with PAPS according to the international consensus criteria for APS. The mean age of the analyzed patients was 45.97 +/- 12.72. The disease duration above 5 years was present in 31/70 of patients. Concentrations of analyzed antibodies were measured by ELISA. Cutoff values were set in accordance to the manufacturers' recommendations. History of recurrent pregnancy loss was associated with double positivity for aanxA5 IgM and LA (chi (2) = 4.000, P = 0.046) and triple positivity for aanxA5 IgM + LA + a beta 2GPI IgM (chi (2) = 4.168, P = 0.041). Venous thromboses were associated with triple positivity for aanxA5 IgM + aCLIgG + a beta 2GPI IgM (chi (2) = 3.965, P = 0.046). The IgG isotype of aanxA5 Abs was in positive correlation with aCL Abs of the IgG (r = 0.310, P = 0.009) and IgM (r = 0.254, P = 0.034) isotype. The presence of the clinical manifestations of PAPS is increasing with the number of positive conventional aPL and the IgM aanxA5 Abs tests. This new combination of Abs is beneficial even when the number of patients with positivity for aanxA5 Abs is low. This is important in further detection of patients prone to recurrence of thrombotic episodes.
PB  - Springer London Ltd, London
T2  - Clinical Rheumatology
T1  - The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome
VL  - 35
IS  - 5
SP  - 1361
EP  - 1365
DO  - 10.1007/s10067-016-3230-0
ER  - 

@article{
author = "Becarević, Mirjana and Stojanović, Ljudmila and Ignjatović, Svetlana and Dopsaj, Violeta",
year = "2016",
abstract = "We evaluated the importance of anti-annexin A5 antibodies (aanxA5 Abs) for clinical (thrombosis and/or recurrent pregnancy loss) and serologic (presence of antiphospholipid antibodies: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta 2 glycoprotein I (a beta 2GPI) antibodies) features of patients with primary antiphospholipid syndrome (PAPS). Our study included 70 patients with PAPS according to the international consensus criteria for APS. The mean age of the analyzed patients was 45.97 +/- 12.72. The disease duration above 5 years was present in 31/70 of patients. Concentrations of analyzed antibodies were measured by ELISA. Cutoff values were set in accordance to the manufacturers' recommendations. History of recurrent pregnancy loss was associated with double positivity for aanxA5 IgM and LA (chi (2) = 4.000, P = 0.046) and triple positivity for aanxA5 IgM + LA + a beta 2GPI IgM (chi (2) = 4.168, P = 0.041). Venous thromboses were associated with triple positivity for aanxA5 IgM + aCLIgG + a beta 2GPI IgM (chi (2) = 3.965, P = 0.046). The IgG isotype of aanxA5 Abs was in positive correlation with aCL Abs of the IgG (r = 0.310, P = 0.009) and IgM (r = 0.254, P = 0.034) isotype. The presence of the clinical manifestations of PAPS is increasing with the number of positive conventional aPL and the IgM aanxA5 Abs tests. This new combination of Abs is beneficial even when the number of patients with positivity for aanxA5 Abs is low. This is important in further detection of patients prone to recurrence of thrombotic episodes.",
publisher = "Springer London Ltd, London",
journal = "Clinical Rheumatology",
title = "The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome",
volume = "35",
number = "5",
pages = "1361-1365",
doi = "10.1007/s10067-016-3230-0"
}

Becarević, M., Stojanović, L., Ignjatović, S.,& Dopsaj, V.. (2016). The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. in Clinical Rheumatology
Springer London Ltd, London., 35(5), 1361-1365.
https://doi.org/10.1007/s10067-016-3230-0

Becarević M, Stojanović L, Ignjatović S, Dopsaj V. The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. in Clinical Rheumatology. 2016;35(5):1361-1365.
doi:10.1007/s10067-016-3230-0 .

Becarević, Mirjana, Stojanović, Ljudmila, Ignjatović, Svetlana, Dopsaj, Violeta, "The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome" in Clinical Rheumatology, 35, no. 5 (2016):1361-1365,
https://doi.org/10.1007/s10067-016-3230-0 . .